Psychedelic Science, Contemplative Practices, and Indigenous and Other Traditional Knowledge Systems: Towards Integrative Community-Based Approaches in Global Health.

Autor: Urrutia J; Department of Psychiatry, Yale University, New Haven, CT, USA.; Prisons Group Legal Clinic, Universidad de los Andes Medical School, Bogotá, Colombia., Anderson BT; Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA., Belouin SJ; United States Public Health Service, Department of Health and Human Services (DHHS), Rockville, MD, USA.; Substance Abuse and Mental Health Services Administration (SAMHSA), DHHS, Rockville, MD, USA.; Office of Science and Medicine, DHHS, Washington, DC, USA.; Office of the Assistant Secretary, DHHS, Washington, DC, USA.; Pain and Palliative Care, National Institutes of Health Clinical Center, Bethesda, MD, USA., Berger A; Pain and Palliative Care, National Institutes of Health Clinical Center, Bethesda, MD, USA., Griffiths RR; Center for Psychedelic and Consciousness Research, Johns Hopkins University, Baltimore, MD, USA.; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Grob CS; David Geffen School of Medicine, University of California (UCLA), Los Angeles, CA, USA.; Division of Child and Adolescent Psychiatry, Harbor-UCLA Medical Center, Torrance, CA, USA., Henningfield JE; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Research, Health Policy and Abuse Liability, Pinney Associates, Bethesda, MD, USA., Labate BC; Chacruna Institute, San Francisco, CA, USA., Maier LJ; Global Drug Survey., Maternowska MC; Moray House School of Education and Sport, University of Edinburgh, Edinburgh, Scotland, United Kingdom., Weichold F; Office of the Chief Scientist, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA., Yaden DB; Center for Psychedelic and Consciousness Research, Johns Hopkins University, Baltimore, MD, USA.; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Magar V; (formerly) Office of the Director General, World Health Organization, Geneva, Switzerland.

Publikováno v: Journal of psychoactive drugs [J Psychoactive Drugs] 2023 Nov-Dec; Vol. 55 (5), pp. 523-538. Date of Electronic Publication: 2023 Oct 24.

Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.

Autor: Zia FZ; Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis, OCCAM 9609 Medical Center Drive, Suite 1W-706, Rockville, MD, 20850, USA. Electronic address: ziaf@mail.nih.gov., Baumann MH; Designer Drug Research Unit (DDRU) Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Drive, Suite 4400, Baltimore, MD, USA., Belouin SJ; United States Public Health Service, Germantown, MD, USA; Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD, USA; Pain and Palliative Care, National Institutes of Health Clinical Center, Bethesda, MD, USA., Dworkin RH; University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; Department of Anesthesiology, Critical Care and Pain Management, Hospital for Special Surgery Research Institute, New York, NY, USA., Ghauri MH; Spine and Pain Clinics of North America, Fair Oaks Medical Building, 4001 Fair Ridge Drive, Suite 202, Fairfax, VA, USA; University of Virginia (UVA) Health System, Departments of Anesthesiology and Pain Management, 1215 Lee Street, Charlottesville, VA, 22903, USA., Hendricks PS; Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, 1665 University Blvd Birmingham, AL 3522, USA., Henningfield JE; PineyAssociates, Inc, 4800 Montgomery Lane, Suite 400, Bethesda, MD, USA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Lanier RK; PineyAssociates, Inc, 4800 Montgomery Lane, Suite 400, Bethesda, MD, USA., Ross S; NYU Langone Center for Psychedelic Medicine, NYU Grossman School of Medicine, One Park Ave, New York, NY, 10016, USA., Berger A; Pain and Palliative Care, National Institutes of Health Clinical Center, Bethesda, MD, USA.

Publikováno v: Neuropharmacology [Neuropharmacology] 2023 Aug 01; Vol. 233, pp. 109528. Date of Electronic Publication: 2023 Apr 02.

Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.

Autor: Henningfield JE; PinneyAssociates, Inc, 4800 Montgomery Lane, Suite 400, Bethesda, MD, USA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: jhenning@pinneyassociates.com., Coe MA; PinneyAssociates, Inc, 4800 Montgomery Lane, Suite 400, Bethesda, MD, USA., Griffiths RR; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Belouin SJ; Substance Abuse and Mental Health Services Administration, Rockville, MD, USA., Berger A; Chief of Pain and Palliative Care, Senior Research Clinician (Full Professor). National Institutes of Health Clinical Center, Bethesda, MD, USA., Coker AR; MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA; Department of Neurology, University of California, San Francisco, CA, USA., Comer SD; Columbia University, Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA., Heal DJ; DevelRx Ltd. BioCity, Nottingham, And Department of Pharmacy and Pharmacology University of Bath, Bath, UK., Hendricks PS; Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, USA., Nichols CD; Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, USA., Sapienza F; Partner, The Drug and Chemical Advisory Group, LLC, Fairfax, VA, USA., Vocci FJ; Friends Research Institute, Baltimore, MD, USA., Zia FZ; Department of Health & Human Services National Institutes of Health, National Cancer Institute Division of Cancer Treatment & Diagnosis, Washington, DC, USA.

Publikováno v: Neuropharmacology [Neuropharmacology] 2022 Nov 01; Vol. 218, pp. 109220. Date of Electronic Publication: 2022 Aug 17.